B cell development, autoimmunity and immune regulation

B 细胞发育、自身免疫和免疫调节

• 批准号: MR/Y033701/1
• 负责人: Richard Cornall
• 金额: $ 238.38万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FY033701%2F1
• 关键词: cell; development; autoimmunity; immune; regulation

Our goal is to understand how the immune system regulates the response to self- and foreign antigens, including how B cells are selected during their development and ontogeny, the causes of human immunodeficiency and how insights from these can help us to improve the normal immune response to antigens, and how dysregulation of the immune response leads to systemic autoimmune disease. We have a longstanding interest in how checkpoint receptor agonists may be used to suppress inflammation and autoimmune disease in humans. More recently, we have started to investigate the immune pathology of lupus and other autoimmune kidney diseases, to improve diagnosis and stratify patients, and test new therapeutic targets. We address these questions with a variety of functional, genetic and therapeutic approaches. Our experiments use transgenic mice, molecular tools and models that can be used to track cells and characterise the immune response to antigens, self-tolerance and B cell selection. We use gene targeting to model human disease and gain insights into new mechanisms, and we are developing single-cell approaches, including spatial imaging, to characterise the immune response and the pathology of disease. We have formed a university spin-out company, MIROBIO, to translate our discoveries into clinical practice.

我们的目标是了解免疫系统如何调节对自我和外国抗原的反应，包括如何在其发育和个体发育过程中选择B细胞，人类免疫缺陷的原因以及这些洞察力如何帮助我们改善对抗原的正常免疫反应以及免疫反应的正常免疫反应，以及免疫反应导致系统性自动疾病。我们对检查点受体激动剂如何用于抑制人类的炎症和自身免疫性疾病有很长的兴趣。最近，我们开始研究狼疮和其他自身免疫性肾脏疾病的免疫病理学，以改善诊断和分层患者，并测试新的治疗靶标。我们采用各种功能，遗传和治疗方法来解决这些问题。我们的实验使用转基因小鼠，分子工具和模型，可用于跟踪细胞并表征对抗原，自耐耐受性和B细胞选择的免疫反应。我们使用基因靶向来建模人类疾病并获得对新机制的见解，并且我们正在开发包括空间成像在内的单细胞方法，以表征免疫反应和疾病的病理。我们已经成立了一家大学纺织公司Mirobio，将我们的发现转化为临床实践。